MOHW to expand the bioequivalence-tested drugs for speedy substitute dispensing

Published: 2003-04-10 07:00:00

Updated: 2003-04-10 07:00:00

The Ministry of Health and Welfare announced it would draw up a rule to revise the reimbursement price criteria for bioequivalence-tested items, to this effect that the ceiling price of items eligible for bioequivalence tesing is determined by 80 percent of the maximum price of original drugs.

...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK